Immunologic priming by one dose of haemophilus influenzae type b conjugate vaccine in infancy

Journal of Infectious Diseases

Volumn 172, Issue 5, 1995, Pages 1268-1272

  Kurikka, Sari ^a   KäYhty, Helena ^a   Saarinen, Leena ^a   RöNnberg, Pirjo Riitta ^a   Eskola, Juhani ^a   MäKelä, P Helena ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ARTICLE; CHILD; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; INFANT; INFECTION CONTROL; INFECTION PREVENTION; INTRAMUSCULAR DRUG ADMINISTRATION; NORMAL HUMAN; PRIORITY JOURNAL;

AGE FACTORS; AGING; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; COMPARATIVE STUDY; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMAN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC MEMORY; INFANT; NEISSERIA MENINGITIDIS; POLYSACCHARIDES, BACTERIAL; SUPPORT, NON-U.S. GOV'T; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 0028783360     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/172.5.1268     Document Type: Article

References (26)

1. World Health Organization. Acceleration of research in relation to the Children’s Vaccine Initiative [editorial]. Bull World Health Organ 1991;69:791-793
2. Eskola J, Käyhty H, Takala A, et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990;323:1381-1387
3. Black SB, Shinefield HR, Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61, 080 children. Pediatr Infect Dis J 1991;10:97-104
4. Santosham M, Wolf M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer membrane protein complex. N Engl J Med 1991;324:1767-1772
5. Vadheim CM, Greenberg DP, Partidge S, Jing J, Ward JI, Kaiser-UCLA Vaccine Study Group. Effectiveness and safety of a Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants. Pediatrics 1993;92:272-279
6. Clements DA, Booy R, Dagan R, et al. Comparison of the epidemiology and cost of Haemophilus influenzae type b disease in five western countries. Pediatr Infect Dis J 1993; 12:362-367
7. Bulkow LR, Wainwright RB, Letson GW, Chang SJ, Ward JI. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr Infect Dis J 1993; 12:484-492
8. Käyhty H, Eskola J, Peltola H, et al. Antibody responses to four Haemophilus influenzae type b conjugate vaccines. Am J Dis Child 1991; 145: 223-227
9. Barington T, Gyhrs A, Kristensen K, Heilman C. Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect Immun 1994;62:9-14
10. Granoff DM, Holmes SJ, Osterblom MT, et al. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J Infect Dis 1993; 168:663-671
11. Mäkelä PH, Peltola H, Käyhty H, et al. Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis 1977; 190(suppl):43-50
12. Mäkelä O, Mattila P, Rautonen N, Seppälä I, Eskola J, Käyhty H. Isotype concentrations of human antibodies to Haemophilus influenzae type b polysaccharide (Hib) in young adults immunized with the polysaccharide as such or conjugated to a protein (diphtheria toxoid). J Immunol 1987;139:1999-2004
13. Calandra GB, Luckas LJ, Jonas LC, et al. Anti-PRP antibody levels after a primary series of PRP-OMPC and persistence of antibody titres following primary and booster doses. Vaccine 1993; 11(suppl 1):58-62
14. Holmes SJ, Murphy TV, Anderson RS, et al. Immunogenicity of four Haemophilus influenzae type b conjugate vaccines in 17- to 19-month-old children. J Pediatr 1991;118:364-371
15. Ahonkhai VI, Lukács LJ, Jonas LC, et al. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHib): clinical evaluation. Pediatrics 1990;85(suppl):676-681
16. Claesson BA, Trollfors B, Lagergard T, et al. Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children. J Pediatr 1988;112:695-702
17. Schlesinger Y, Granoff DM, Vaccine Study Group. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. JAMA 1992;267:1489-1495
18. Hetherington SV, Rutkowski AF. Antibody affinity in infants after immunization with conjugated capsular polysaccharide from Haemophilus influenzae type b. J Infect Dis 1990; 162:1185-1188
19. Käyhty H, Eskola J, Peltola H, Saarinen L, Mäkelä PH. High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccines. J Tnfect Dis 1992; 165(suppl 1): 165-166
20. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1993;340:592-594
21. Barbour ML, Booy R, Crook DW, et al. Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine. Pediatr Infect Dis J 1993; 12:478-484
22. Ward J, Brenneman G, Letson GW, Heyward WI, Alaska H. influenzae Vaccine Study Group. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska native infants. N Engl J Med 1990;323:1393-1401
23. Paradiso PR, Hogerman DA, Madore DV, et al. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccine in young infants. Pediatrics 1993;92:827-832
24. Dagan R, Botujansky C, Watemberg N, et al. Safety and immunogenicity in young infants of Haemophilus influenzae b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis-enhanced inactivated poliovirus vaccine. Pediatr Infect Dis J 1994; 13:356-361
25. Coursaget P, Fritzeil B, Blondeau C, Salio P, Diop-Mar I. Simultaneous injection of plasma-derived or recombinant hepatitis B vaccines with yellow fever and killed polio vaccines. Vaccine 1995;13:109-111
26. Mulholland EK, Todd J, Rowe M, et al. Persistence of antibody at 18 months following vaccination of young Gambian infants with PRP-OMPC Haemophilus influenzae type b conjugate vaccine. Ann Tropic Paediatr 1993;13:153-158